Research Associate / Senior Research Associate, Platform Enhancement

TCR² Therapeutics Inc. is an immuno-oncology company developing novel cancer therapies that unleash the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated activity against both hematological and solid tumor targets in preclinical models and believes its TRuC™-reprogrammed T cells will serve as the engine for important therapies.  TCR² was founded by MPM Capital and has scientific operations in Cambridge, MA to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

The successful candidate will join the Innovation group utilizing cellular assays, immune cell profiling, and molecular biology for the development and optimization of novel cell therapies for the treatment of cancer. The position represents an excellent growth and learning opportunity, working closely with experienced scientists in a fast-paced and highly collaborative environment.


  • Design and execute studies to generate and functionally characterize effector T cells, including but not limited to isolation and culturing T cells, lentiviral transduction, cytokine release assays, killing assays, and exhaustion assays.

  • Support laboratory activities by helping maintain equipment and lab supplies.

  • Document and analyze experimental data for written or oral presentation.

  • Present results at lab meetings and interdepartmental team meetings.


  • B.S./M.S. degree in immunology or molecular and cell biology preferred, with at least 3 years of experience, preferably in industry.

  • Strong in vitro skills with experience in primary cell culture, maintaining cell lines, ELISA-based assays (Luminex/MSD), qRT-PCR, and immune phenotyping by multi-color flow cytometry.

  • Working knowledge of immuno-oncology, including chimeric antigen receptor (CAR) T-cells, T cell activation, T cell-mediated cytotoxicity, T cell exhaustion and animal models of adoptive therapy is desirable.

  • Familiarity with molecular biological techniques for genetic perturbation (shRNA, CRISPR etc.) along with lentiviral or retroviral production and transduction of mammalian cells is a plus.

  • Demonstrate willingness to learn and apply new technologies and procedures.

  • Outstanding communication, critical thinking, organizational skills, and attention to detail is essential.

Interested candidates should send their resume to